Highlights
- Tenofovir alafenamide fumarate (TAF)–emtricitabine backbone was superior to standard care for second-line ART in African children with HIV.
- Dolutegravir anchor therapy achieved higher rates of viral suppression than ritonavir-boosted lopinavir or atazanavir.
- Safety profiles were comparable across regimens, with no significant differences in serious adverse events.
- Ritonavir-boosted darunavir and atazanavir are viable alternatives for second-line therapy.
Clinical Background and Disease Burden
